TY - JOUR
T1 - Spina bifida and pediatric cancers
AU - Heck, Julia E.
AU - Lee, Pei Chen
AU - Wu, Chia Kai
AU - Li, Chung Yi
AU - He, Di
AU - Federman, Noah
AU - Yu, Fei
AU - Olsen, Jorn
AU - Ritz, Beate
AU - Arah, Onyebuchi A.
AU - Hansen, Johnni
N1 - Funding Information:
Authors would like to thank Drs. Negar Omidakhsh and Hsin-Yun Tsai for their help with the manuscript. The Danish study was supported by the US National Institutes of Health (R03ES021643, R21CA175959). The Taiwan study was supported by the Alex’s Lemonade Stand Foundation (grant 17-01882). Ms. He was supported by funds from the Tobacco-Related Disease Research Program of the University of California, Grant Number T29DT0485. Dr. Federman was supported by NIH/NCATS Grant # UL1TR001881.
Publisher Copyright:
© 2020 Taylor & Francis Group, LLC.
PY - 2020/10/2
Y1 - 2020/10/2
N2 - Spina bifida has been reported to co-occur with pediatric cancer, but comprehensive evaluations remained elusive. We investigated this co-occurrence in two large, population-based studies in Taiwan (N = 1900 cancer cases, 2,077,137 controls) and Denmark (N = 5508 cases, 137,700 controls). Analyses in Denmark were restricted to the period before prenatal diagnostics became available (2004) and pregnancy terminations of fetuses with birth defects became more common. Using national patient and cancer registries, we linked spina bifida and cancer diagnoses among cases and non-cases. The risk of spina bifida among all cancer cases was increased and similar in Denmark [odds ratio (OR)=8.4, 95% confidence interval (CI) 5.1-13.8] and Taiwan (OR = 8.5, 95% CI 4.0-17.8), particularly for central nervous system (CNS) tumors (Denmark: OR = 16.3, 95% CI 8.1-33.0; Taiwan: OR = 26.6, 95% CI 8.5, 83.1), including benign CNS tumors (Denmark: OR = 41.5, 95% CI 21.2, 81.4). These findings suggest the need for comprehensive investigation of shared risk factors in the link between spina bifida and pediatric cancer.
AB - Spina bifida has been reported to co-occur with pediatric cancer, but comprehensive evaluations remained elusive. We investigated this co-occurrence in two large, population-based studies in Taiwan (N = 1900 cancer cases, 2,077,137 controls) and Denmark (N = 5508 cases, 137,700 controls). Analyses in Denmark were restricted to the period before prenatal diagnostics became available (2004) and pregnancy terminations of fetuses with birth defects became more common. Using national patient and cancer registries, we linked spina bifida and cancer diagnoses among cases and non-cases. The risk of spina bifida among all cancer cases was increased and similar in Denmark [odds ratio (OR)=8.4, 95% confidence interval (CI) 5.1-13.8] and Taiwan (OR = 8.5, 95% CI 4.0-17.8), particularly for central nervous system (CNS) tumors (Denmark: OR = 16.3, 95% CI 8.1-33.0; Taiwan: OR = 26.6, 95% CI 8.5, 83.1), including benign CNS tumors (Denmark: OR = 41.5, 95% CI 21.2, 81.4). These findings suggest the need for comprehensive investigation of shared risk factors in the link between spina bifida and pediatric cancer.
UR - http://www.scopus.com/inward/record.url?scp=85084300852&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084300852&partnerID=8YFLogxK
U2 - 10.1080/08880018.2020.1760409
DO - 10.1080/08880018.2020.1760409
M3 - Article
C2 - 32364426
AN - SCOPUS:85084300852
VL - 37
SP - 630
EP - 636
JO - Pediatric Hematology and Oncology
JF - Pediatric Hematology and Oncology
SN - 0888-0018
IS - 7
ER -